Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial
2024 · Cancer Immunology Immunotherapy · 6 citations
https://doi.org/10.1007/s00262-024-03744-z